A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation

• Status: Completed
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

This trial is investigating the efficacy and safety of highly purified human chorionic gonadotropin (HP-hCG) and recombinant human chorionic gonadotropin (rhCG) for triggering of final follicular maturation in women undergoing controlled ovarian stimulation

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Chorionic Gonadotropin

Criteria

Inclusion Criteria:

• Pre-menopausal females between the ages of 18 and 39 years

• Documented history of infertility

• Body mass index (BMI) between 17.5 and 32.0 kg/m2

• Regular menstrual cycles

Exclusion Criteria:

• Known endometriosis stage III and IV

• Known polycystic ovarian syndrome (PCOS)

• History of recurrent miscarriage

• History of more than three previous controlled ovarian stimulation cycles